Elsevier

Parkinsonism & Related Disorders

Volume 77, August 2020, Pages 160-162
Parkinsonism & Related Disorders

Correspondence
Levodopa response in later stages of Parkinson's disease: A case-control study

https://doi.org/10.1016/j.parkreldis.2019.10.027Get rights and content

Section snippets

Funding source

The study had no specific funding.

Authors’ contributions

1. Research project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique.

Dr. Margherita Fabbri: 1A, 1C, 2A, 3A;

Prof. Miguel Coelho: 1A, 1B, 2C, 3B;

Daisy Abreu: 1B, 2A, 2B;

Prof. Joaquim J Ferreira: 1A, 1B, 3B;

Declaration of competing interest

Dr. Margherita Fabbri: no conflict of interest to report. Stock Ownership in medically-related fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; Honoraria to speak: none; Grants: AbbVie; Intellectual Property Rights: none; Expert Testimony: none; Contracts: none; Royalties: none; Other: none.

Prof. Miguel Coelho: no conflict of interest to report. Stock Ownership in medically-related fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; Honoraria

Acknowledgments

The authors thank all the patients and their families for participating in this study.

References (6)

There are more references available in the full text version of this article.

Cited by (4)

  • Parkinson's disease

    2021, The Lancet
    Citation Excerpt :

    There is a heightened interest in the most severe stages of Parkinson's disease. New studies identified considerable disabilities, but also recognised remaining treatment options.137,138 Adjusting levodopa can alleviate some symptoms in advanced Parkinson's disease, albeit at the risk of worsening dyskinesias or psychosis.137

View full text